ABSTRACT
Introduction
Prevalence of diabetes mellitus (DM) is increasing rapidly worldwide. The number of people with diabetes is expected to grow by 380 million by the year 2025. Cardiovascular risk is 2-4 fold increased in diabetic patients compared to nondiabetic individuals, and cardiovascular events are still the leading cause of morbidity and mortality in patients with DM [1] . Antiplatelet agents are used for both the primary and secondary prevention of cardiovascular disease in diabetic patients [2] . Aspirin exerts its principal antithrombotic activity by irreversibly inhibits the COX-1 enzyme and thereby inhibiting the thromboxane A 2, , which is a potent mediator of platelet aggregation and activation [3] . Recurrence of thrombotic events despite treatment with aspirin at recommended antithrombotic doses raises the concept of "aspirin resistance," describing the inefficacy or limited efficacy of the drug. Aspirin resistance, defined as failure of suppression of thromboxane generation, increases the risk of cardiovascular events [4] . There are continuing discrepancies regarding the cause of biochemical aspirin resistance, its clinical outcomes and the role of aspirin in cardiovascular risk management in patients with diabetes. All these emphasize need to understand the mechanisms that contribute to interactions between diabetes and aspirin to determine the role of specific aspirin and antithrombotic treatment in general in treating cardiovascular events in diabetic individuals. Here, we aimed to investigate the frequency of aspirin resistance in patients with Type 1 and 2 diabetes and to study its association with metabolic parameters.
Material and Methods
This study enrolled patients with Type 1 and 2 DM who were hospitalized at the Endocrinology service of Dicle University Faculty of Medicine or who presented to the endocrinology outpatient clinic between March 2007 and May 2009. An age-matched control group was also included for comparisons. Subjects were provided information about the study, and their informed consents were obtained before they were enrolled in the study. One hundred and fifty eight patients with Type 2 DM (64 males and 94 females, mean age: 57±24) and 164 healthy controls (78 males, 86 females, mean age: 55±19), and 30 patients with Type 1 DM (16 males, 14 females; mean age: 22±9) and 41 healthy subjects (21 males, 20 females; mean age: 27±7) were compared.
Subjects were subdivided into four groups as:
• patients only with Type 1 DM • patients only with Type 2 DM • patients with Type 2 DM and coronary heart disease • healthy individuals as a control group.
Subjects' detailed histories were taken, and they underwent physical examinations. They were questioned for age, sex, waist circumference, smoking habits, and alcohol consumption, the presence of hypertension, cerebrovascular events (CVE), coronary heart disease (CHD), hyperlipidemia, chronic renal disease, chronic hepatic disease, infection, malignancy and concomitant medications and their answers were recorded. Those with a history of myocardial infarction and diagnoses confirmed with ECG or Doppler Echocardiography were considered to have CHD. Subjects with previous malignancies, renal or hepatic failure, and using a NSAID were excluded from the study to prevent possible interferences with aspirin metabolism. Blood pressure measurements of all subjects were performed before physical examination following at least 5 minutes of rest from the right brachial artery using a sphygmomanometer. Body weights were measured with light clothes on and without shoes. Waist circumferences (cm) were taken at the umbilicus following a normal expiration on an empty stomach when the subjects wore gowns and were standing. Subjects' body mass indices were calculated using the formula, weight (kg)/height 2 (meters). Blood samples for the study were taken following 10-12 hours of fasting at 8.00 a.m. which was used for glucose, urea, creatinine, HbA1c, total cholesterol, LDL-cholesterol, VLDLcholesterol, HDL-cholesterol and triglyceride measurements. Biochemical analyses were performed by the central laboratory of Dicle University. Platelet functions and aspirin resistances of all subjects used in the study were analyzed using PFA-100. 2.7 ml of blood samples of each subject were collected in vacuum tubes containing 0.3 sodium citrate 3.8%. Obtained blood samples were studied within 3 hours with PFA-100 using collagen/epinephrine (Col/Epi) and collagen/ADP (Col/ADP) for platelet functions at Day 8 for patients who had been using aspirin regularly for the past seven days. Membrane surface of blood stimulated by epinephrine and ADP despite regular treatment with aspirin was evaluated by measuring closure time with thrombus. Closure times, as measured by Col/Epi cartridges, shorter than 165 seconds and Col/ADP closure times shorter than 114 seconds were considered as aspirin resistance.
Statistical Analysis
Independent t-test and chi-square test were used for the statistical analyses in the present study. The level of significance was set at p<0.05.
Results
In the present study 158 patients with Type 2 DM (64 males, 94 females) were compared to 164 age-matched healthy controls (78 males, 86 females) and 30 patients with Type 1 DM (16 males, 14 females) were compared to 41 age-matched healthy controls for the prevalence of aspirin resistance in diabetic patients. Associations between aspirin resistance and age, sex, BMI, blood pressure, HbA1c, lipid values and aspirin dose were investigated in patients with both Type 2 and Type 1 DM. The mean age of patients with Type 2 DM was 57±24 (mean ± SD), ranging between 32 and 77. The mean age of patients with Type 1 DM was 22±9 (mean ± SD), ranging between 16 and 31.There were no statistically significant differences between mean ages with and without aspirin resistance.
Aspirin resistance was determined in 72 of 158 patients with Type 2 DM (45.6%) and in 47 of 164 healthy controls (28.6%). A comparison of patients with Type 2 and healthy controls yielded a higher frequency of aspirin resistance in patients with Type 2 DM, which was statistically significant (p=0.001). Aspirin resistance was noted in 21 of 41 patients with Type 2 DM with a history of coronary heart disease (51.2%) ( Table 1) . Although aspirin resistance was more frequent in patients with Type 2 DM + coronary heart disease compared to those with Type 2 DM alone, the difference was not statistically significant (p=0.467).
Aspirin resistance was noted for 15 of 30 patients with Type 1 DM (50%) and 5 of 41 healthy controls (12.2%) ( Table 2 ). The frequency of aspirin resistance was statistically significantly higher in patients with Type1 DM than the healthy controls (p=0.001).
Seventy-two of 158 patients (64 males, 94 females) with Type 2 diabetes had aspirin resistance (45.6%). Twenty-nine of 64 male patients (40.3%) and 43 of 94 female patients (59.7%) had aspirin resistance. Comparisons of both sexes demonstrated that aspirin resistance was more frequent among female patients, but the difference was not statistically significant.
Aspirin resistance was noted in 15 of 30 patients (16 males, 14 females) with Type 1 diabetes (50%). The frequency of aspirin resistance among men were 9/16 (60%) and 6/14 in females (40%). Comparisons of both sexes among patients with Type 1 diabetes showed a higher frequency of aspirin resistance in male patients than female patients, but no statistically significant difference was noted. Aspirin resistance was identified in 25 of 47 (53%) patients with Type 2 diabetes with a smoking habit and in 47 of 111 non-smoker patients with Type 2 diabetes. No significant difference was noted between aspirin resistance frequency among Type 2 diabetic patients with and without smoking habit. Three of 8 (37.5%) Type 1 diabetic patients with smoking habit 
Discussion
In diabetic patients, aspirin therapy is recommended for the secondary prevention of cardiovascular disease and primary prevention in patients at increased cardiovascular risk [2) ]. Compared to non-diabetic patients, increased platelet turnover, poor glucose control, increased protein glycosylation has been suggested as the possible mechanisms of aspirin resistance in diabetic patients [5] . The literature is indicating an inadequate protection by aspirin in diabetes. A meta-analysis of 287 randomized studies has shown a 22% reduction in the risk of ischemic events with antithrombotic treatment, whereas the risk reduction in the diabetic subgroup was only 7%, not reaching statistical significance [6] .
This result has also been reflected in the Primary Prevention Project study reporting that cardiovascular risk reduction was not significant in the presence of diabetes [7] .
The first randomized trial to reveal that aspirin is associated with negative clinical outcomes was carried out by Gum et al. [8] in stable angina pectoris using aggregometer and PFA-100 tests. More than a three-fold increased risk of death, myocardial infarction (MI) and CVE has been reported for patients with aspirin resistance after a follow-up period of about two years. Varying rates of aspirin resistance were determined with same and different methods in different patient populations have been reported from clinical trials. According to these trials, about 10-40% of diabetic patients have biochemical aspirin resistance [9, 10] .
In the present study, we identified a higher rate of aspirin resistance in diabetic patients compared to healthy controls. Increased frequency of aspirin resistance identified among patients with Type 2 DM may be due to the prothrombotic process to which hyperglycemia or insulin resistance plus dyslipidemia contributes in these patients. This high prevalence of aspirin resistance in patients with Type 2 DM demonstrates the failure of aspirin as an antiplatelet treatment recommended as a part of standard therapy and indicates that different treatment approaches should be assessed to prevent thromboembolic events in this patient population. Higher frequencies of aspirin resistance identified for patients with both Type 1 and Type 2 diabetes suggest a role of hyperglycemia in the etiology.
Our results showed that there were no differences between subjects with and without aspirin resistance regarding mean daily aspirin dose (300mg/day). Moreover, no correlations between aspirin resistance and sex, smoking, BMI, HbA1c, and hypertension were observed in patients with Type 2 or Type 1 DM. However, our results revealed a significant relation between aspirin resistance and LDL-cholesterol in patients with Type 2 DM (p=0.020). There are two large trials investigating the frequency of aspirin resistance in patients with diabetes. FatehMoghadam et al. [10] , in their study of 172 diabetic patients, identified complete resistance in 21.5% and partial resistance in 16.9% of the patients. In another study by Mehta et al. [9] involving 203 patients, the authors identified an aspirin resistance frequency of 18.7% in their sample. Lack of control groups in these studies makes suspicion whether aspirin resistance has a higher rate in diabetic patients. On the other hand, studies involving control groups, have a limited number of subjects. These studies reported a higher frequency of aspirin resistance in diabetic subjects compared to non-diabetics. Compared with the results of previous studies, higher frequency of aspirin resistance identified in the present study may be due to the genetic polymorphism. It is clear that further studies are needed to elucidate this estimation.
Our results indicated the higher rates of aspirin resistance in patients with both Type 1 and Type 2 DM patients in comparison to the control group. Statistical significance in both patient groups and similar rates of aspirin resistance between Type 1 and 2 diabetes suggests that increased aspirin resistance might be associated with hyperglycemia, a mechanism inherent to diabetes. A relation between glycation and acetylation has been shown, supporting the involvement of hyperglycemia. Besides, platelet glycation and increases in coagulation factor proteins may interact with acetylation process in the presence of diabetes to contribute to aspirin resistance [11] . If competition between acetylation and glycation of proteins is influential on aspirin effectiveness, it is important to determine whether good glycemic control improves the effectiveness of aspirin or whether aspirin dose should be increased in poor glycemic control [12] . This suggests that aspirin resistance may overcome by administering higher doses of aspirin to diabetic patients with aspirin resistance. Takahashi et al. [13] have shown that increasing aspirin dose may be beneficial in eliminating aspirin resistance in diabetics. In the Early Treatment Diabetic Retinopathy Study (ETDRS) investigating the effectiveness of higher doses of aspirin, a nonsignificant decrease in cardiovascular events was achieved with 650 mg/day aspirin dose in diabetic subjects [14] . On the other hand, there are also findings suggesting that adding clopidogrel to aspirin in patients with acute coronary syndromes or those who underwent percutaneous interventions resulted in improved outcomes without leading to an increased risk [15] [16] [17] . Different antiplatelet agents or their combinations, however, may offer more efficient choices. Ticlopidine has reduced the frequency of transient ischemic attacks and strokes in cases where aspirin failed to produce desired clinical outcomes [18] . In the CAPRIE trial (Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events), clopidogrel resulted in a 7-8% relative decrease in the risk of recurrent stroke, MI, and vascular deaths compared to aspirin (19) . In the CURE trial (Clopidogrel in Unstable Angina to Prevent Recurrent Events), patients with acute coronary syndrome started aspirin treatment at 75-325 mg and were randomized to clopidogrel or placebo. The addition of clopidogrel resulted in a decreased risk of cardiovascular events and stroke, regardless of the aspirin dose [20] .
The mechanisms that underlie aspirin resistance to aspirin therapy in diabetic patients are not clear, but hyperglycemia seems to be one of these factors. High blood glucose potentially predisposes patients to treatment failure by leading to glycation of platelet proteins and making them less available for acetylation. This interaction between acetylation and glycation may explain the higher efficacy of clopidogrel compared to low-dose aspirin in preventing vascular events in diabetes. Therefore, we suggest that screening of aspirin resistance and alternative methods to improve response in those with aspirin resistance might make sense. Hypothetically, administering higher doses of aspirin or combining aspirin with another antiplatelet agent such as clopidogrel as two simple approaches may help increase the effectiveness of antiplatelet treatment in diabetes.
Conclusion
Our study demonstrated that aspirin resistance is significantly higher in patients with Type 1 and Type 2 DM compared to healthy individuals. Also, increased aspirin resistance between Type 1 and Type 2 diabetes suggest that aspirin resistance might strongly be associated with hyperglycemia. More advanced clinical trials and basic investigations are required to understand the reasons for clinical failures with aspirin treatment and to elucidate the involved mechanisms to determine the prevalence of biochemical aspirin resistance in diabetic individuals.
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